Bioventus granted FDA clearance for bioactive bone graft strips
Bioventus LLC has announced its new variation of its Signafuse Bioactive Bone Graft has received clearance from the FDA, according to a company press release.
The Signafuse Bioactive Bone Graft, which was previously available in putty form, will come in the form of a strip. The strips will comprise of 55% bioglass by weight, which has been shown to induce higher levels of osteoblast differentiation compared with other synthetic bone graft strips, the company said.
The strips will come in numerous sizes between 25 mm and 200 mm in length, with longer strips being an option for larger multilevel procedures, according to the press release.
“We also believe Signafuse in the strip format will provide efficiencies for the hospital, either by opening fewer packages or cost savings opportunities vs. alternative grafts,” John Nosenzo, Bioventus chief commercial officer said in the release.
Bioventus said the new strip variation will be available nationally in the third quarter of 2020.